ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
SAN DIEGO–(BUSINESS WIRE)–Jan. 25, 2016– ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer. Dr. Owen will be responsible for evolving and executing the clinical development programs for ACADIA’s product candidates and report to Serge Stankovic, M.D., M.S.P.H., ACADIA’s Executive Vice President, Head of Research and Development.
“Randy brings significant expertise in clinical research and development along with a deep knowledge of CNS science,” said Steve Davis, ACADIA’s President and Chief Executive Officer. “He has led the development and approval of important therapeutics in CNS and will be a valued addition to the ACADIA team as we seek to help patients who suffer from serious neurological and psychiatric disorders.”
Dr. Owen most recently served as Vice President, U.S. Clinical Affairs at Lundbeck LLC from 2010 to 2016. During his tenure, his team of medical experts and scientists made significant contributions in drug development across a wide range of neurological and psychiatric disorders, including innovative development programs in schizophrenia, Alzheimer’s disease and stroke, as well as pediatric and adult orphan indications. Prior to joining Lundbeck, Dr. Owen served as Group Director, Global Clinical Research at Bristol-Myers Squibb Company where he co-led the life-cycle management of Abilify® during a period of product extensions in psychiatric indications in the United States and Europe. Dr. Owen received his B.A. at Haverford College and his M.D. at East Tennessee State University, Quillen College of Medicine. He completed his residency at Emory University and is board certified in psychiatry.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition. The FDA has classified the NUPLAZID NDA as having Priority Review status. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.com to which we regularly post copies of our press releases as well as additional information and through which interested parties can subscribe to receive e-mail alerts.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the potential for NUPLAZID (pimavanserin) to be the first drug approved in the United States for Parkinson’s disease psychosis (PDP) and the potential timing of such approval, if approved at all, by the FDA; the potential contributions of Dr. Owen to ACADIA; the progress, timing and results of ACADIA’s drug discovery and development programs, either alone or with a partner, including the progress and expected timing of clinical trials; and the benefits to be derived from ACADIA’s product candidates, including pimavanserin. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, approval and commercialization, and collaborations with others, and the fact that past results of clinical trials and past regulatory decisions may not be indicative of future trial results or future regulatory decisions, respectively. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2014 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.